Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2024 Mar;84(3):363-368. doi: 10.1007/s40265-024-02012-9.
Berdazimer topical gel, 10.3% (ZELSUVMI™) is a nitric oxide (NO) releasing topical gel developed by Novan Inc. (a Ligand Pharmaceuticals company) for the treatment of molluscum contagiosum (MC). Novan has used their proprietary NO-based technology platform (NITRICIL™), which stores gaseous NO species on large polymers, in the development of berdazimer topical gel, 10.3%. In January 2024, berdazimer topical gel, 10.3% was approved for the topical treatment of MC in adult and paediatric patients 1 year of age and older in the USA. This article summarizes the milestones in the development of berdazimer topical gel, 10.3% leading to this first approval for the treatment of MC.
贝达西莫特局部凝胶，10.3%（ZELSUVMI™）是一种由 Novan Inc.（利兰制药公司）开发的释放一氧化氮（NO）的局部凝胶，用于治疗传染性软疣（MC）。Novan 公司利用其专有的基于一氧化氮的技术平台（NITRICIL™），将气态的 NO 物种储存在大聚合物上，开发了贝达西莫特局部凝胶，10.3%。2024 年 1 月，贝达西莫特局部凝胶，10.3%在美国获得批准，用于治疗 1 岁及以上成人和儿科患者的 MC。本文总结了贝达西莫特局部凝胶，10.3%的开发过程中的重要里程碑，最终获得了治疗 MC 的首次批准。
